Skip to results

Keyword or reference number

Keyword or reference number

Decision date

Decision date

Technology type

Technology type

Topic selection decision

Topic selection decision

Type

Type

Showing 1 to 13 of 13

Guidance in topic selection
TitleTechnology typeDecisionDecision date
Selumetinib granules for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children 1 to 6 years TS ID 12092MedicineNot selected
Evinacumab for treating homozygous familial hypercholesterolemia in children aged 5 to 11 TS ID 11806MedicineNot selected
Guselkumab for treating chronic plaque psoriasis in children aged 6 to 17 years TSID 12002MedicineNot selected
Ivacaftor for treating cystic fibrosis with mutations in the CFTR gene in babies and children aged 1 to 3 months or weighing 3 kg to 24 kg TS ID 11894MedicineNot selected
Spineform Hemibridge endoscopic vertebral stapling to reduce curvature in the growing scoliotic spine in childrenProcedureNot selected
Elexacaftor–tezacaftor–ivacaftor and ivacaftor for treating cystic fibrosis with at least 1 F508del mutation in the CFTR gene in children aged 2 to 5 TS ID 10767MedicineNot selected
Baricitinib for treating moderate to severe atopic dermatitis in children and young people aged 2 to 17 [TS ID 10639]MedicineNot selected
Subcutaneous belimumab for treating systemic lupus erythematosus in children aged 5 to 17 TS ID 11828MedicineNot selected
Dulaglutide for treating type 2 diabetes in children and young people TS ID 10660MedicineNot selected
Dupilumab for children with severe atopic dermatitis [TS ID 10434]MedicineNot selected
Dupilumab for maintenance treatment of uncontrolled moderate to severe asthma in children 6 to 11 years [TS ID 10085]MedicineNot selected
Moor LDLS-BI for assessing burn depth and healing potential in children and adultsDeviceNot selected
Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]MedicineNot selected

Results per page

  1. 10
  2. 25
  3. 50
  4. All